mergers & acquisitions

CRO and analytics giant IQvia, the product of the IMS Health-Quintiles merger, quietly purchased UK-based bioinformatics company Linguamatics a month ago.

BioMérieux will adapt Invisible Sentinel's Veriflow DNA signature capturing technology on its Gene-Up system for food pathogen detection.

ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.

Labcyte has developed an acoustic droplet ejection technology called Echo that uses sound energy for the contactless transfer of samples and reagents.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

Arbor Biosciences' portfolio includes custom DNA microarrays and oligonucleotide libraries, as well as a line of targeted sequencing panels.

With the acquisition, Qiagen will integrate N-of-One’s MarkerMine database into its core technology to help customers design new, targeted therapies.

The company also reaffirmed its guidance for the fourth quarter, and continues to expect revenues of $46.5 million to $48.0 million and EPS of $.09 to $.11.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.